Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians
Open Access
- 30 August 2025
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (9) , 1317-1325
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) presents an urgent challenge that necessitates improved early risk identification. We investigated the association between predictors of PDAC present at least two years before diagnosis and PDAC occurence. Methods: This case-control study used electronic health records from The Health Improvement Network Database (UK). Cases (10,575) were matched with controls (105,750) in a 1:10 ratio by gender, age, follow-up duration, and year of inclusion in the database. Variables included clinical features, comorbidities and blood result abnormalities, reported at least 2 years before PDAC diagnosis or equivalent timeframe for controls. Conditional logistic regression model with backward estimated odds ratios (OR) and 95% confidence interval (CI). Results: Electronic health records of cases reported higher prevalence of alcohol intake, cigarette smoking, dyslipidemia, increased blood pressure, and diabetes of more than four years’ duration. Independent risk factors included pancreatic cysts (OR = 4.39), pancreatitis (OR = 2.16), dyslipidemia (OR = 1.50), smoking (OR = 1.09), and alcohol intake (OR = 1.09). Laboratory markers associated with higher risk included elevated alkaline phosphatase (OR = 3.21), bilirubin (OR = 2.48), alanine aminotransferase (OR = 1.76), erythrocyte sedimentation rate (OR = 1.27), and decreased albumin (OR = 1.54). Conclusions: Primary care electronic records can identify individuals at medium-term increased risk of PDAC, thus raises the opportunity to develop early detection models and address modifiable factors.Keywords
This publication has 54 references indexed in Scilit:
- GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/ObesityJAMA Oncology, 2024
- Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug InteractionsJAMA Network Open, 2022
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerJAMA Oncology, 2022
- Early screening and diagnosis strategies of pancreatic cancer: a comprehensive reviewCancer Communications, 2021
- Diabetes, Weight Change, and Pancreatic Cancer RiskJAMA Oncology, 2020
- Screening for Pancreatic CancerJAMA, 2019
- Screening for Pancreatic CancerJAMA, 2019
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJAMA, 2013
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer ResectionJAMA, 2010
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007